|
1
|
Thai AA, Solomon BJ, Sequist LV, Gainor JF
and Heist RS: Lung cancer. Lancet. 398:535–554. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vallone S, Beunders I and Szmytke E: Lung
cancer patient needs in different countries. Lung Cancer Manag.
6:1–4. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Polanski J, Jankowska-Polanska B,
Rosinczuk J, Chabowski M and Szymanska-Chabowska A: Quality of life
of patients with lung cancer. Onco Targets Ther. 9:1023–1028.
2016.PubMed/NCBI
|
|
4
|
Wood DE, Kazerooni EA, Baum SL, Eapen GA,
Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner
RP, et al: Lung cancer screening, version 3.2018, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
16:412–441. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miyasaka Y, Sato H, Okano N, Kubo N,
Kawamura H and Ohno T: A promising treatment strategy for lung
cancer: A combination of radiotherapy and immunotherapy. Cancers
(Basel). 14:2032021. View Article : Google Scholar
|
|
6
|
Tang FH, Wong HYT, Tsang PSW, Yau M, Tam
SY, Law L, Yau K and Wong J, Farah FHM and Wong J: Recent
advancements in lung cancer research: A narrative review. Transl
Lung Cancer Res. 14:975–990. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ibodeng GO, Uche IN, Mokua R, Galo M,
Odigwe B, Galeas JN and Dasgupta S: A snapshot of lung cancer:
Where are we now?-A narrative review. Ann Transl Med. 11:2612023.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Larsen JE and Minna JD: Molecular biology
of lung cancer: Clinical implications. Clin Chest Med. 32:703–740.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mohiuddin M: Anti-PD-1/PD-L1 immunotherapy
as a potential treatment option for lung cancer: A perspective
analysis of opportunities and challenges. Health Sci Rep.
9:e717492026. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang X, Lamberti G, Di Federico A, Alessi
J, Ferrara R, Sholl ML, Awad MM, Vokes N and Ricciuti B: Tumor
mutational burden for the prediction of PD-(L)1 blockade efficacy
in cancer: Challenges and opportunities. Ann Oncol. 35:508–522.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng W, Kang K, Zhao A and Wu Y: Dual
blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung
cancer. J Hematol Oncol. 17:542024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sui H, Ma N, Wang Y, Li H, Liu X, Su Y and
Yang J: Anti-PD-1/PD-L1 therapy for non-small-cell lung cancer:
Toward personalized medicine and combination strategies. J Immunol
Res. 2018:69849482018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu L, Yang L, Li H, Shang T and Liu L:
The tumor microenvironment in lung cancer: Heterogeneity,
therapeutic resistance and emerging treatment strategies (Review).
Int J Oncol. 68:112026.
|
|
14
|
Deng Z, Ma X, Zou S, Tan L and Miao T:
Innovative technologies and their clinical prospects for early lung
cancer screening. Clin Exp Med. 25:2122025. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Seijo LM, Peled N, Ajona D, Boeri M, Field
JK, Sozzi G, Pio R, Zulueta JJ, Spira A, Massion PP, et al:
Biomarkers in lung cancer screening: Achievements, promises, and
challenges. J Thorac Oncol. 14:343–357. 2019. View Article : Google Scholar
|
|
16
|
Shi Y, Fan T, Yang Y, Liu J, Ouyang J and
Dai J: Beyond structural domains: The emerging roles of PDLIM2 in
cellular signaling and cancer progression. Front Physiol.
16:15692852025. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo ZS and Qu Z: PDLIM2: Signaling
pathways and functions in cancer suppression and host immunity.
Biochim Biophys Acta Rev Cancer. 1876:1886302021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fisher LAB and Schöck F: The unexpected
versatility of ALP/Enigma family proteins. Front Cell Dev Biol.
10:9636082022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Healy MD and Collins BM: The PDLIM family
of actin-associated proteins and their emerging role in membrane
trafficking. Biochem Soc Trans. 51:2005–2016. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang X, Xu Z, Jiang S, Wang H, Xiao M,
Shi Y and Wang K: PDZ and LIM domain-encoding genes: Their role in
cancer development. Cancers (Basel). 15:50422023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Christensen NR, Čalyševa J, Fernandes EFA,
Lüchow S, Clemmensen LS, Haugaard-Kedström LM and Strømgaard K: PDZ
domains as drug targets. Adv Ther (Weinh). 2:18001432019.
View Article : Google Scholar
|
|
22
|
Lee HJ and Zheng JJ: PDZ domains and their
binding partners: Structure, specificity, and modification. Cell
Commun Signal. 8:82010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu X and Fuentes EJ: Emerging themes in
PDZ domain signaling: Structure, function, and inhibition. Int Rev
Cell Mol Biol. 343:129–218. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ye F and Zhang M: Structures and target
recognition modes of PDZ domains: Recurring themes and emerging
pictures. Biochem J. 455:1–14. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sala S and Oakes PW: LIM domain proteins.
Curr Biol. 33:R339–R341. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kadrmas JL and Beckerle MC: The LIM
domain: From the cytoskeleton to the nucleus. Nat Rev Mol Cell
Biol. 5:920–931. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zheng Q and Zhao Y: The diverse
biofunctions of LIM domain proteins: Determined by subcellular
localization and protein-protein interaction. Biol Cell.
99:489–502. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Matthews JM and Sunde M: Zinc
fingers-folds for many occasions. IUBMB Life. 54:351–355. 2002.
View Article : Google Scholar
|
|
29
|
Torrado M, Senatorov VV, Trivedi R, Fariss
RN and Tomarev SI: Pdlim2, a novel PDZ-LIM domain protein,
interacts with alpha-actinins and filamin A. Invest Ophthalmol Vis
Sci. 45:3955–3963. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Loughran G, Healy NC, Kiely PA, Huigsloot
M, Kedersha NL and O'Connor R: Mystique is a new insulin-like
growth factor-I-regulated PDZ-LIM domain protein that promotes cell
attachment and migration and suppresses Anchorage-independent
growth. Mol Biol Cell. 16:1811–1822. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tanaka T, Soriano MA and Grusby MJ: SLIM
is a nuclear ubiquitin E3 ligase that negatively regulates STAT
signaling. Immunity. 22:729–736. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ungureanu D and Silvennoinen O: SLIM trims
STATs: Ubiquitin E3 ligases provide insights for specificity in the
regulation of cytokine signaling. Sci STKE. 2005:pe492005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hershko A and Ciechanover A: The ubiquitin
system. Annu Rev Biochem. 67:425–479. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Komander D and Rape M: The ubiquitin code.
Annu Rev Biochem. 81:203–229. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee JS, Kim HY, Kwon YT, Ji CH, Lee SJ and
Kim SB: The ubiquitin code in disease pathogenesis and progression:
Composition, characteristics and its potential as a therapeutic
target. Discov Med. 37:203–221. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hochstrasser M: Ubiquitin-dependent
protein degradation. Annu Rev Genet. 30:405–439. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ziv I, Matiuhin Y, Kirkpatrick DS,
Erpapazoglou Z, Leon S, Pantazopoulou M, Kim W, Gygi SP,
Haguenauer-Tsapis R, Reis N, et al: A perturbed ubiquitin landscape
distinguishes between ubiquitin in trafficking and in proteolysis.
Mol Cell Proteomics. 10:M111.0097532011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Koo SY, Park EJ, Noh HJ, Jo SM, Ko BK,
Shin HJ and Lee CW: Ubiquitination links DNA damage and repair
signaling to cancer metabolism. Int J Mol Sci. 24:84412023.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bhoj VG and Chen ZJ: Ubiquitylation in
innate and adaptive immunity. Nature. 458:430–437. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zou T and Lin Z: The involvement of
ubiquitination machinery in cell cycle regulation and cancer
progression. Int J Mol Sci. 22:57542021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shaid S, Brandts CH, Serve H and Dikic I:
Ubiquitination and selective autophagy. Cell Death Differ.
20:21–30. 2013. View Article : Google Scholar
|
|
42
|
Hicke L: A new ticket for entry into
budding vesicles-ubiquitin. Cell. 106:527–530. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sheng X, Xia Z, Yang H and Hu R: The
ubiquitin codes in cellular stress responses. Protein Cell.
15:157–190. 2024. View Article : Google Scholar :
|
|
44
|
Bedford L, Lowe J, Dick LR, Mayer RJ and
Brownell JE: Ubiquitin-like protein conjugation and the
ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov.
10:29–46. 2011. View Article : Google Scholar
|
|
45
|
Damgaard RB: The ubiquitin system: From
cell signalling to disease biology and new therapeutic
opportunities. Cell Death Differ. 28:423–426. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang X, Lan T, Zhang B, Tao X, Qi W, Xie
K, Cai Y, Liu C, Han J and Wu H: Targeting ubiquitination in
disease and therapy. Signal Transduct Target Ther. 10:4242025.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Toma-Fukai S and Shimizu T: Structural
diversity of ubiquitin E3 ligase. Molecules. 26:66822021.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang H, Peng J, Li H, Lan Y, Guo J, Qiu Q
and Huang X: E3 ubiquitin ligases: Structures, biological
functions, diseases, and therapy. MedComm (2020). 6:e705282025.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Uchida C and Kitagawa M: RING-, HECT-, and
RBR-type E3 ubiquitin ligases: Involvement in human cancer. Curr
Cancer Drug Targets. 16:157–174. 2016. View Article : Google Scholar
|
|
50
|
Yang Q, Zhao J, Chen D and Wang Y: E3
ubiquitin ligases: Styles, structures and functions. Mol Biomed.
2:232021. View Article : Google Scholar :
|
|
51
|
Antoniou N, Lagopati N, Balourdas DI,
Nikolaou M, Papalampros A, Vasileiou PVS, Myrianthopoulos V,
Kotsinas A, Shiloh Y, Liontos M and Gorgoulis VG: The role of E3,
E4 ubiquitin ligase (UBE4B) in human pathologies. Cancers (Basel).
12:622019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hoppe T: Multiubiquitylation by E4
enzymes: 'one size' doesn't fit all. Trends Biochem Sci.
30:183–187. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Koegl M, Hoppe T, Schlenker S, Ulrich HD,
Mayer TU and Jentsch S: A novel ubiquitination factor, E4, is
involved in multiubiquitin chain assembly. Cell. 96:635–644. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Matthews JM, Bhati M, Lehtomaki E,
Mansfield RE, Cubeddu L and Mackay JP: It takes two to tango: The
structure and function of LIM, RING, PHD and MYND domains. Curr
Pharm Des. 15:3681–3696. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tanaka T, Grusby MJ and Kaisho T:
PDLIM2-mediated termination of transcription factor NF-kappaB
activation by intranuclear sequestration and degradation of the p65
subunit. Nat Immunol. 8:584–591. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
56
|
Shin C, Ito Y, Ichikawa S, Tokunaga M,
Sakata-Sogawa K and Tanaka T: MKRN2 is a novel ubiquitin E3 ligase
for the p65 subunit of NF-κB and negatively regulates inflammatory
responses. Sci Rep. 7:460972017. View Article : Google Scholar
|
|
57
|
Jodo A, Shibazaki A, Onuma A, Kaisho T and
Tanaka T: PDLIM7 synergizes with PDLIM2 and p62/Sqstm1 to inhibit
inflammatory signaling by promoting degradation of the p65 subunit
of NF-κB. Front Immunol. 11:15592020. View Article : Google Scholar
|
|
58
|
Lu J, Zhang J, Jiang H, Hu Z, Zhang Y, He
L, Yang J, Xie Y, Wu D, Li H, et al: Vangl2 suppresses NF-κB
signaling and ameliorates sepsis by targeting p65 for
NDP52-mediated autophagic degradation. Elife. 12:RP879352024.
View Article : Google Scholar
|
|
59
|
Nguyen HC, Wang W and Xiong Y: Cullin-RING
E3 ubiquitin ligases: Bridges to destruction. Subcell Biochem.
83:323–347. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lydeard JR, Schulman BA and Harper JW:
Building and remodelling Cullin-RING E3 ubiquitin ligases. EMBO
Rep. 14:1050–1061. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Duda DM, Scott DC, Calabrese MF, Zimmerman
ES, Zheng N and Schulman BA: Structural regulation of cullin-RING
ubiquitin ligase complexes. Curr Opin Struct Biol. 21:257–264.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sugimoto-Ishige A, Jodo A and Tanaka T:
Fbxo16 mediates degradation of NF-κB p65 subunit and inhibits
inflammatory response in dendritic cells. Front Immunol.
16:15241102025. View Article : Google Scholar
|
|
63
|
Sun F, Xiao G and Qu Z: PDLIM2 is a novel
E5 ubiquitin ligase enhancer that stabilizes ROC1 and recruits the
ROC1-SCF ubiquitin ligase to ubiquitinate and degrade NF-κB RelA.
Cell Biosci. 14:992024. View Article : Google Scholar
|
|
64
|
Qu Z, Fu J, Yan P, Hu J, Cheng SY and Xiao
G: Epigenetic repression of PDZ-LIM domain-containing protein 2:
Implications for the biology and treatment of breast cancer. J Biol
Chem. 285:11786–11792. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Cox OT, Edmunds SJ, Simon-Keller K, Li B,
Moran B, Buckley NE, Bustamante-Garrido M, Healy N, O'Flanagan CH,
Gallagher WM, et al: PDLIM2 is a marker of adhesion and β-catenin
activity in triple-negative breast cancer. Cancer Res.
79:2619–2633. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kang M, Lee KH, Lee HS, Park YH, Jeong CW,
Ku JH, Kim HH and Kwak C: PDLIM2 suppression efficiently reduces
tumor growth and invasiveness of human castration-resistant
prostate cancer-like cells. Prostate. 76:273–285. 2016. View Article : Google Scholar
|
|
67
|
Yuk HD, Lee KH, Lee HS, Jeong SH, Kho Y,
Jeong CW, Kim HH, Ku JH and Kwak C: PDLIM2 suppression inhibit
proliferation and metastasis in kidney cancer. Cancers (Basel).
13:29912021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Qu Z, Yan P, Fu J, Jiang J, Grusby MJ,
Smithgall TE and Xiao G: DNA methylation-dependent repression of
PDZ-LIM domain-containing protein 2 in colon cancer and its role as
a potential therapeutic target. Cancer Res. 70:1766–1772. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Oh BY, Cho J, Hong HK, Bae JS, Park WY,
Joung JG and Cho YB: Exome and transcriptome sequencing identifies
loss of PDLIM2 in metastatic colorectal cancers. Cancer Manag Res.
9:581–589. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Jiang X, Chu Z, Cao Y, Tang Y, Shi Y and
Shi X: PDLIM2 prevents the malignant phenotype of hepatocellular
carcinoma cells by negatively regulating β-catenin. Cancer Gene
Ther. 28:1113–1124. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zhang X, Shan W, Hu Q, Wu K, Ji M, Wang X,
Liu Z, Zhang B, Shi H and Cao K: PDLIM2 deficiency mediated by
PBXIP1 promotes the proliferation of HCC cells through reducing the
polyubiquitination and degradation of TRIM27. Eur J Med Res.
30:12082025. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhao L, Yu C, Zhou S, Lau WB, Lau B, Luo
Z, Lin Q, Yang H, Xuan Y, Yi T, et al: Epigenetic repression of
PDZ-LIM domain-containing protein 2 promotes ovarian cancer via
NOS2-derived nitric oxide signaling. Oncotarget. 7:1408–1420. 2016.
View Article : Google Scholar :
|
|
73
|
Lv W, Guo H, Wang J, Ma R, Niu L and Shang
Y: PDLIM2 can inactivate the TGF-β/Smad pathway to inhibit the
malignant behavior of ovarian cancer cells. Cell Biochem Funct.
41:542–552. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhang Z, Shang B, Mao X, Shi Y, Zhang G
and Wang D: Prognostic risk models using epithelial cells identify
β-sitosterol as a potential therapeutic target against esophageal
squamous cell carcinoma. Int J Gen Med. 17:1193–1211. 2024.
View Article : Google Scholar
|
|
75
|
Sun F, Xiao Y and Qu Z: Oncovirus Kaposi
sarcoma herpesvirus (KSHV) represses tumor suppressor PDLIM2 to
persistently activate nuclear factor κB (NF-κB) and STAT3
transcription factors for tumorigenesis and tumor maintenance. J
Biol Chem. 290:7362–7368. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Wurster KD, Hummel F, Richter J, Giefing
M, Hartmann S, Hansmann ML, Kreher S, Köchert K, Krappmann D,
Klapper W, et al: Inactivation of the putative ubiquitin-E3 ligase
PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma.
Leukemia. 31:602–613. 2017. View Article : Google Scholar :
|
|
77
|
Zeng Y, Lin D, Gao M, Du G and Cai Y:
Systematic evaluation of the prognostic and immunological role of
PDLIM2 across 33 cancer types. Sci Rep. 12:19332022. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Sun F, Li L, Yan P, Zhou J, Shapiro SD,
Xiao G and Qu Z: Causative role of PDLIM2 epigenetic repression in
lung cancer and therapeutic resistance. Nat Commun. 10:53242019.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Sun F, Yan P, Xiao Y, Zhang H, Shapiro SD,
Xiao G and Qu Z: Improving PD-1 blockade plus chemotherapy for
complete remission of lung cancer by nanoPDLIM2. Elife.
12:RP896382024. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Shi H, Ji Y, Li W, Zhong Y and Ming Z:
PDLIM2 acts as a cancer suppressor gene in non-small cell lung
cancer via the down regulation of NF-κB signaling. Mol Cell Probes.
53:1016282020. View Article : Google Scholar
|
|
81
|
Yang JX, Chuang YC, Tseng JC, Liu YL, Lai
CY, Lee AY, Huang CF, Hong YR and Chuang TH: Tumor promoting effect
of PDLIM2 downregulation involves mitochondrial ROS, oncometabolite
accumulations and HIF-1α activation. J Exp Clin Cancer Res.
43:1692024. View Article : Google Scholar
|
|
82
|
Gong X, Du D, Deng Y, Zhou Y, Sun L and
Yuan S: The structure and regulation of the E3 ubiquitin ligase
HUWE1 and its biological functions in cancer. Invest New Drugs.
38:515–524. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zhang M, Zhang Z, Tian X, Zhang E, Wang Y,
Tang J and Zhao J: NEDD4L in human tumors: Regulatory mechanisms
and dual effects on anti-tumor and pro-tumor. Front Pharmacol.
14:12917732023. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Yang X, Zhu J, Tao X, Gao F, Cai Y, Lv Y,
Xie S, Xie K, Lan T, Han J and Wu H: Challenges and opportunities
for the diverse substrates of SPOP E3 ubiquitin ligase in cancer.
Theranostics. 15:6111–6145. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Esposito JE, De Iuliis V, Avolio F,
Liberatoscioli E, Pulcini R, Di Francesco S, Pennelli A, Martinotti
S and Toniato E: Dissecting the functional role of the TRIM8
protein on cancer pathogenesis. Cancers (Basel). 14:23092022.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Guo T, Tang H, Yuan Z, Zhang E and Wang X:
The dual role of USP11 in cancer. J Oncol. 2022:99639052022.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Wistuba II, Behrens C, Virmani AK,
Milchgrub S, Syed S, Lam S, Mackay B, Minna JD and Gazdar AF:
Allelic losses at chromosome 8p21-23 are early and frequent events
in the pathogenesis of lung cancer. Cancer Res. 59:1973–1979.
1999.PubMed/NCBI
|
|
88
|
Kurimoto F, Gemma A, Hosoya Y, Seike M,
Takenaka K, Uematsu K, Yoshimura A, Shibuya M and Kudoh S:
Unchanged frequency of loss of heterozygosity and size of the
deleted region at 8p21-23 during metastasis of lung cancer. Int J
Mol Med. 8:89–93. 2001.PubMed/NCBI
|
|
89
|
Kang J: Genomic alterations on 8p21-p23
are the most frequent genetic events in stage I squamous cell
carcinoma of the lung. Exp Ther Med. 9:345–350. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Macartney-Coxson DP, Hood KA, Shi HJ, Ward
T, Wiles A, O'Connor R, Hall DA, Lea RA, Royds JA, Stubbs RS and
Rooker S: Metastatic susceptibility locus, an 8p hot-spot for
tumour progression disrupted in colorectal liver metastases: 13
candidate genes examined at the DNA, mRNA and protein level. BMC
Cancer. 8:1872008. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Bhattacharya N, Chunder N, Basu D, Roy A,
Mandal S, Majumder J, Roychowdhury S and Panda CK: Three discrete
areas within the chromosomal 8p21.3-23 region are associated with
the development of breast carcinoma of Indian patients. Exp Mol
Pathol. 76:264–271. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Hosseini HA, Ahani A, Galehdari H,
Froughmand AM, Hosseini M, Masjedizadeh A and Zali MR: Frequent
loss of heterozygosity at 8p22 chromosomal region in diffuse type
of gastric cancer. World J Gastroenterol. 13:3354–3358. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Thiagalingam S, Foy RL, Cheng KH, Lee HJ,
Thiagalingam A and Ponte JF: Loss of heterozygosity as a predictor
to map tumor suppressor genes in cancer: Molecular basis of its
occurrence. Curr Opin Oncol. 14:65–72. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Zhang X and Sjöblom T: Targeting loss of
heterozygosity: A novel paradigm for cancer therapy.
Pharmaceuticals (Basel). 14:572021. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lee E and Hong JH: Oxidative stress
defense module in lung cancers: Molecular pathways and therapeutic
approaches. Antioxidants (Basel). 14:8572025. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Valavanidis A, Vlachogianni T, Fiotakis K
and Loridas S: Pulmonary oxidative stress, inflammation and cancer:
Respirable particulate matter, fibrous dusts and ozone as major
causes of lung carcinogenesis through reactive oxygen species
mechanisms. Int J Environ Res Public Health. 10:3886–3907. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Goldkorn T, Filosto S and Chung S: Lung
injury and lung cancer caused by cigarette smoke-induced oxidative
stress: Molecular mechanisms and therapeutic opportunities
involving the ceramide-generating machinery and epidermal growth
factor receptor. Antioxid Redox Signal. 21:2149–2174. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Caliri AW, Tommasi S and Besaratinia A:
Relationships among smoking, oxidative stress, inflammation,
macromolecular damage, and cancer. Mutat Res Rev Mutat Res.
787:1083652021. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Li L, Sun F, Han L, Liu X, Xiao Y, Gregory
AD, Shapiro SD, Xiao G and Qu Z: PDLIM2 repression by ROS in
alveolar macrophages promotes lung tumorigenesis. JCI Insight.
6:e1443942021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Liu S, Sun X, Wang M, Hou Y, Zhan Y, Jiang
Y, Liu Z, Cao X, Chen P, Liu Z, et al: A microRNA 221- and
222-mediated feedback loop maintains constitutive activation of
NFκB and STAT3 in colorectal cancer cells. Gastroenterology.
147:847–859.e11. 2014. View Article : Google Scholar
|
|
101
|
Oltulu YM, Coskunpinar E, Yildiz P, Aynaci
E, Karimova A and Yaylim I: Investigation of miR221 and miR222 as
biomarkers in non-small cell lung cancer. In Vivo. 37:1603–1608.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Tepebasi MY and Öztürk Ö: miR-21, miR-221,
and miR-222 upregulation in lung cancer promotes metastasis by
reducing oxidative stress and apoptosis. Rev Assoc Med Bras (1992).
69:e202216882023. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Brighenti M: MicroRNA and MET in lung
cancer. Ann Transl Med. 3:682015.PubMed/NCBI
|
|
104
|
Godwin P, Baird AM, Heavey S, Barr MP,
O'Byrne KJ and Gately K: Targeting nuclear factor-kappa B to
overcome resistance to chemotherapy. Front Oncol. 3:1202013.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Lukas K, Nguyen J, Necas C, Dave K and
Venketaraman V: Targeting the NF-κB pathway in cancer: Mechanisms,
resistance, and therapeutic potential across tumor types.
Pharmaceuticals (Basel). 18:17642025. View Article : Google Scholar
|
|
106
|
Godugu D, Chilamakuri R and Agarwal S:
STAT3 axis in cancer and cancer stem cells: From oncogenesis to
targeted therapies. Biochim Biophys Acta Rev Cancer.
1880:1894612025. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Bollrath J and Greten FR: IKK/NF-kappaB
and STAT3 pathways: Central signalling hubs in
inflammation-mediated tumour promotion and metastasis. EMBO Rep.
10:1314–1319. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Grivennikov SI and Karin M: Dangerous
liaisons: STAT3 and NF-kappaB collaboration and crosstalk in
cancer. Cytokine Growth Factor Rev. 21:11–19. 2010. View Article : Google Scholar
|
|
109
|
Lee H, Herrmann A, Deng JH, Kujawski M,
Niu G, Li Z, Forman S, Jove R, Pardoll DM and Yu H: Persistently
activated Stat3 maintains constitutive NF-kappaB activity in
tumors. Cancer Cell. 15:283–293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Squarize CH, Castilho RM, Sriuranpong V,
Pinto DS Jr and Gutkind JS: Molecular cross-talk between the
NFkappaB and STAT3 signaling pathways in head and neck squamous
cell carcinoma. Neoplasia. 8:733–746. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Fan Y, Mao R and Yang J: NF-κB and STAT3
signaling pathways collaboratively link inflammation to cancer.
Protein Cell. 4:176–185. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Morelli M, Madonna S and Albanesi C: SOCS1
and SOCS3 as key checkpoint molecules in the immune responses
associated to skin inflammation and malignant transformation. Front
Immunol. 15:13937992024. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Jiang M, Zhang WW, Liu P, Yu W, Liu T and
Yu J: Dysregulation of SOCS-mediated negative feedback of cytokine
signaling in carcinogenesis and its significance in cancer
treatment. Front Immunol. 8:702017. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Khan MGM, Ghosh A, Variya B, Santharam MA,
Ihsan AU, Ramanathan S and Ilangumaran S: Prognostic significance
of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling
pathway genes in hepatocellular carcinoma. BMC Cancer. 20:7742020.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Jafarzadeh A, Zandvakili R, Jafarzadeh Z
and Nemati M: Dysregulated expression of the suppressors of
cytokine signaling (SOCS) contributes to the development of
prostate cancer. Pathol Res Pract. 262:1555582024. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Zhang Y, Chu M, Ye M, Yin Y and Chen H:
SOCS3: An immunological biomarker offering potential therapeutic
targets for malignant tumors. Biol Proced Online. 27:362025.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Dai L, Tao Y, Shi Z, Liang W, Hu W, Xing
Z, Zhou S, Guo X, Fu X and Wang X: SOCS3 Acts as an
onco-immunological biomarker with value in assessing the tumor
microenvironment, pathological staging, histological subtypes,
therapeutic effect, and prognoses of several types of cancer. Front
Oncol. 12:8818012022. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Vallespi MG, Mestre B, Marrero MA, Uranga
R, Rey D, Lugiollo M, Betancourt M, Silva K, Corrales D, Lamadrid
Y, et al: A first-in-class, first-in-human, phase I trial of
CIGB-552, a synthetic peptide targeting COMMD1 to inhibit the
oncogenic activity of NF-κB in patients with advanced solid tumors.
Int J Cancer. 149:1313–1321. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Weiskirchen R and Penning LC: COMMD1, a
multi-potent intracellular protein involved in copper homeostasis,
protein trafficking, inflammation, and cancer. J Trace Elem Med
Biol. 65:1267122021. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Yeh DW, Chen YS, Lai CY, Liu YL, Lu CH, Lo
JF, Chen L, Hsu LC, Luo Y, Xiang R and Chuang TH: Downregulation of
COMMD1 by miR-205 promotes a positive feedback loop for amplifying
inflammatory- and stemness-associated properties of cancer cells.
Cell Death Differ. 23:841–852. 2016. View Article : Google Scholar :
|
|
121
|
Jin J, Lu Z, Wang X, Liu Y, Han T, Wang Y,
Wang T, Gan M, Xie C, Wang J and Yu B: E3 ubiquitin ligase TRIM7
negatively regulates NF-kappa B signaling pathway by degrading p65
in lung cancer. Cell Signal. 69:1095432020. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Alomari M: TRIM21-A potential novel
therapeutic target in cancer. Pharmacol Res. 165:1054432021.
View Article : Google Scholar
|
|
123
|
Zhang L, Lin W, Liu J, Hong Y, Cao Z, Yu
Z, Feng X and Gao Y: Ubiquitination-based classification and a
prognostic signature identify the role of TRIM21 in sarcoma
progression. Curr Med Chem. 33:3246–3271. 2026.
|
|
124
|
Yang Y, Hao X, Zhang J, Gao T, Huo M, Liu
W, Hu T, Ma T, Yuan B, Zhang M, et al: The E3 ligase TRIM22
functions as a tumor suppressor in breast cancer by targeting CCS
for proteasomal degradation to inhibit STAT3 signaling. Cancer
Lett. 600:2171572024. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du
Y, Shen J, Chen CT, Huo L, Hsu MC, et al: KEAP1 E3 ligase-mediated
downregulation of NF-kappaB signaling by targeting IKKbeta. Mol
Cell. 36:131–140. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Wang Y, Ren F, Wang Y, Feng Y, Wang D, Jia
B, Qiu Y, Wang S, Yu J, Sung JJ, et al: CHIP/Stub1 functions as a
tumor suppressor and represses NF-κB-mediated signaling in
colorectal cancer. Carcinogenesis. 35:983–991. 2014. View Article : Google Scholar
|
|
127
|
Le TH, Sun F, Xiao G and Qu Z:
NanoPDLIM2-based combination therapy for lung cancer treatment in
mouse preclinical studies. Bio Protoc. 15:e54372025. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Ward PS and Thompson CB: Metabolic
reprogramming: A cancer hallmark even warburg did not anticipate.
Cancer Cell. 21:297–308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Park WH: Mitochondrial reprogramming in
lung cancer: A therapeutic vulnerability and a strategy for
reversing drug resistance. J Pathol. 269:149–163. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Roberts ER and Thomas KJ: The role of
mitochondria in the development and progression of lung cancer.
Comput Struct Biotechnol J. 6:e2013030192013. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Parma B, Wurdak H and Ceppi P: Harnessing
mitochondrial metabolism and drug resistance in non-small cell lung
cancer and beyond by blocking heat-shock proteins. Drug Resist
Updat. 65:1008882022. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Mao Y, Xia Z, Xia W and Jiang P: Metabolic
reprogramming, sensing, and cancer therapy. Cell Rep.
43:1150642024. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Du H, Xu T, Yu S, Wu S and Zhang J:
Mitochondrial metabolism and cancer therapeutic innovation. Signal
Transduct Target Ther. 10:2452025. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Pandey S, Anang V and Schumacher MM:
Mitochondria driven innate immune signaling and inflammation in
cancer growth, immune evasion, and therapeutic resistance. Int Rev
Cell Mol Biol. 386:223–247. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Liu H, Pan M, Li Y, Huang Z, Li H, Zhang
C, Guo C and Wang H: Recent advances and applications of
mitochondria in tumors and inflammation. J Transl Med. 23:7642025.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Cao K, Xu J, Cao W, Wang X, Lv W, Zeng M,
Zou X, Liu J and Feng Z: Assembly of mitochondrial succinate
dehydrogenase in human health and disease. Free Radic Biol Med.
207:247–259. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Wang J, Yuan T, Yang B, He Q and Zhu H:
SDH defective cancers: Molecular mechanisms and treatment
strategies. Cell Biol Toxicol. 41:742025. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Moosavi B, Zhu XL, Yang WC and Yang GF:
Molecular pathogenesis of tumorigenesis caused by succinate
dehydrogenase defect. Eur J Cell Biol. 99:1510572020. View Article : Google Scholar
|
|
139
|
Nazar E, Khatami F, Saffar H and Tavangar
SM: The emerging role of succinate dehyrogenase genes (SDHx) in
tumorigenesis. Int J Hematol Oncol Stem Cell Res. 13:72–82.
2019.PubMed/NCBI
|
|
140
|
Nisr RB, Shah DS, Ganley IG and Hundal HS:
Proinflammatory NFkB signalling promotes mitochondrial dysfunction
in skeletal muscle in response to cellular fuel overloading. Cell
Mol Life Sci. 76:4887–4904. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Capece D, Verzella D, Flati I, Arboretto
P, Cornice J and Franzoso G: NF-κB: blending metabolism, immunity,
and inflammation. Trends Immunol. 43:757–775. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Mateska I, Witt A, Hagag E, Sinha A,
Yilmaz C, Thanou E, Sun N, Kolliniati O, Patschin M, Abdelmegeed H,
et al: Succinate mediates inflammation-induced adrenocortical
dysfunction. Elife. 12:e830642023. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
LaGory EL and Giaccia AJ: The
ever-expanding role of HIF in tumour and stromal biology. Nat Cell
Biol. 18:356–365. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Balamurugan K: HIF-1 at the crossroads of
hypoxia, inflammation, and cancer. Int J Cancer. 138:1058–1066.
2016. View Article : Google Scholar
|
|
145
|
Acuña-Pilarte K and Koh MY: The HIF axes
in cancer: Angiogenesis, metabolism, and immune-modulation. Trends
Biochem Sci. 50:677–694. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Sun SY: Mechanisms of HIF-1α function in
malignant cells and associated therapeutic strategies. J Biochem
Mol Toxicol. 40:e707462026. View Article : Google Scholar
|
|
147
|
Fawzul Ameer S, Abdul Latif MSE and
Ibrahim WN: Hypoxia and HIF signalling in tumour microenvironment:
Linking immune evasion, metabolic rewiring and epigenetic
regulation. Expert Rev Mol Med. 28:e142026. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Ivanov S, Nano O, Hana C, Bonano-Rios A
and Hussein A: Molecular targeting of the isocitrate dehydrogenase
pathway and the implications for cancer therapy. Int J Mol Sci.
25:73372024. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Anthony J, Varalakshmi S, Sekar AK,
Devarajan N, Janakiraman B and Peramaiyan R: Glutaminase-A
potential target for cancer treatment. Biomedicine (Taipei).
14:29–37. 2024. View Article : Google Scholar
|
|
150
|
Pakhira S, Kundu S and Roy SS: The role of
fatty acid oxidation in metabolic crosstalk between tumor cells and
associated factors in the microenvironment. Biochim Biophys Acta
Rev Cancer. 1880:1894472025. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Yu M, Yang D, Chen X, Yang Y, Zhang B,
Jiang X, Xing L, Yang Y, Sun Y and Li N: Metabolic reprogramming in
cancer: Dysregulation of glucose, lipid, and amino acid pathways
and therapeutic opportunities. Mol Biomed. 7:252026. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Fontana F, Giannitti G, Marchesi S and
Limonta P: The PI3K/Akt pathway and glucose metabolism: A dangerous
liaison in cancer. Int J Biol Sci. 20:3113–3125. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Sun X, Ye G, Mai Y, Shu Y, Wang L and
Zhang J: Parkin exerts the tumor-suppressive effect through
targeting mitochondria. Med Res Rev. 43:855–871. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Sun X, Ye G, Li J, Yuan L, Bai G, Xu YJ
and Zhang J: The tumor suppressor Parkin exerts anticancer effects
through regulating mitochondrial GAPDH activity. Oncogene.
43:3215–3226. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Eid N and Kondo Y: Parkin in cancer:
Mitophagy-related/unrelated tasks. World J Hepatol. 9:349–351.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Di Gregorio J, Terreri S, Rossi M,
Battafarano G, Di Giuseppe L, Pagliarosi O, Cilenti L, Ricevuto E,
Zervos AS, Flati V and Del Fattore A: The tumor suppressor role of
mitochondrial E3 ubiquitin ligase MUL1 in osteosarcoma. Biochim
Biophys Acta Mol Cell Res. 1873:1201012026. View Article : Google Scholar
|
|
157
|
Calle X, Garrido-Moreno V, Lopez-Gallardo
E, Norambuena-Soto I, Martinez D, Peñaloza-Otárola A, Troncossi A,
Guerrero-Moncayo A, Ortega A, Maracaja-Coutinho V, et al:
Mitochondrial E3 ubiquitin ligase 1 (MUL1) as a novel therapeutic
target for diseases associated with mitochondrial dysfunction.
IUBMB Life. 74:850–865. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Shimizu K, Nihira NT, Inuzuka H and Wei W:
Physiological functions of FBW7 in cancer and metabolism. Cell
Signal. 46:15–22. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Shen W, Zhou Q, Peng C, Li J, Yuan Q, Zhu
H, Zhao M, Jiang X, Liu W and Ren C: FBXW7 and the Hallmarks of
Cancer: Underlying Mechanisms and Prospective Strategies. Front
Oncol. 12:8800772022. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Li G, Pan W, Wu L, Cai Z, Chen H, Wu X, Yu
T, Liao K, Zhang H, Wen X and Li B: Mitochondrial VHL rewires cell
metabolism in hypoxia. Cell Metab. 38:174–191.e7. 2026. View Article : Google Scholar
|
|
161
|
Lee K and Kim HM: A novel approach to
cancer therapy using PX-478 as a HIF-1α inhibitor. Arch Pharm Res.
34:1583–1585. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Bui BP, Nguyen PL, Lee K and Cho J:
Hypoxia-inducible factor-1: A novel therapeutic target for the
management of cancer, drug resistance, and cancer-related pain.
Cancers (Basel). 14:60542022. View Article : Google Scholar : PubMed/NCBI
|
